During the past decade, Lanzhou University Second Hospital conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 3 clinical trials were completed, i.e. on average, 4.8% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 2 clinical trials were completed. i.e. 4.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lanzhou University Second Hospital" #1 sponsor was "Air Force Military Medical University, China" with 6 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "LanZhou University" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Chengdu Kanghong Biotech Co., Ltd." with 3 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lanzhou University Second Hospital" #1 collaborator was "Jiangsu Suzhong Pharmaceutical Group Co., Ltd." with 2 trials as a collaborator, "LanZhou University" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Beijing Ditan Hospital" with 1 trials as a collaborator. Other collaborators include 49 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Lanzhou University Second Hospital" are "Gastric Cancer" (4 trials), "Functional Dyspepsia" (3 trials), "Hypertension" (3 trials), "Prostate Cancer" (3 trials) and "Dyspepsia" (2 trials). Many other conditions were trialed in "Lanzhou University Second Hospital" in a lesser frequency.

Most popular intervention types in "Lanzhou University Second Hospital" are "Drug" (52 trials), "Other" (4 trials), "Procedure" (4 trials), "Device" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Tirzepatide" (3 trials), "Anlotinib" (2 trials), "Finerenone (BAY94-8862)" (2 trials) and "TQB2450" (2 trials). Other intervention names were less common.

The vast majority of trials in "Lanzhou University Second Hospital" are 62 trials for "All" genders, 4 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Lanzhou University Second Hospital". 2 are not yet recruiting, 32 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Lanzhou University Second Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Lanzhou University Second Hospital, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 8 trials that are defined as “Not Applicable".